United Therapeutics Corp. (UTHR) PT Raised to $435 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $608.49 +1.19%
Rating Summary:
18 Buy, 9 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
18 Buy, 9 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $435.00 (from $328.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- United Therapeutics Corp. (UTHR) PT Raised to $720 at Raymond James
- GXO Logistics Inc. (GXO) PT Raised to $72 at TD Cowen
- United Therapeutics (UTHR) Misses Q3 EPS by 50c, Beats on Revenue
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
